Hereditary factors in pancreatic cancer
- PMID: 12021894
- DOI: 10.1007/s005340200001
Hereditary factors in pancreatic cancer
Abstract
The incidence and the mortality rates for pancreatic cancer are the same, indicating its dismal outlook. Its natural history remains elusive. Cigarette smoking appears to be the most significant environmental culprit. Hereditary factors may account for approximately 5% of the total pancreatic cancer burden. However, when its extant heterogeneity and the reduced penetrance of causal germline mutations are considered, the hereditary incidence may significantly exceed this estimate. Even when endoscopic ultrasound (EUS), the gold standard for pancreatic cancer screening, is utilized, early detection with surgical cure has rarely been accomplished. Needed to ameliorate this problem is research into genetic and environmental risk factors and their interaction. The identification of tumor biomarkers which signal early pathogenetic events, thereby enabling pancreatic cancer to be diagnosed at its earliest possible stage before it has spread to regional lymph nodes or to more distant sites, will improve the outlook. We discuss our research approaches to this problem. Members of families with the p16 germline mutation will undergo EUS coupled with the collection of pancreatic juice for the study of a possible gradient for telomerase activity, K- ras mutations, and cytology. If changes in these putative biomarkers are observed, endoscopic retrograde cholangiopancreatography (ERCP) would be the next diagnostic step. We conclude with a discussion of ethical concerns about this research.
Similar articles
-
Limitations in improving detection of pancreatic adenocarcinoma.Future Oncol. 2009 Jun;5(5):657-68. doi: 10.2217/fon.09.32. Future Oncol. 2009. PMID: 19519205 Review.
-
Hereditary pancreatic cancer: a clinical perspective.Best Pract Res Clin Gastroenterol. 2009;23(2):159-70. doi: 10.1016/j.bpg.2009.02.001. Best Pract Res Clin Gastroenterol. 2009. PMID: 19414143 Review.
-
[Familial pancreatic cancer].Magy Onkol. 2006;50(2):163-8. Epub 2006 Aug 4. Magy Onkol. 2006. PMID: 16888680 Review. Hungarian.
-
Evidence for a major gene influencing risk of pancreatic cancer.Genet Epidemiol. 2002 Aug;23(2):133-49. doi: 10.1002/gepi.1102. Genet Epidemiol. 2002. PMID: 12214307
-
Strategies for screening for pancreatic adenocarcinoma in high-risk patients.Semin Oncol. 2007 Aug;34(4):295-302. doi: 10.1053/j.seminoncol.2007.05.008. Semin Oncol. 2007. PMID: 17674957 Review.
Cited by
-
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.Yonsei Med J. 2005 Aug 31;46(4):519-25. doi: 10.3349/ymj.2005.46.4.519. Yonsei Med J. 2005. PMID: 16127777 Free PMC article.
-
Current treatment strategies for pancreatic cancer in the elderly.Drugs Aging. 2006;23(5):403-10. doi: 10.2165/00002512-200623050-00004. Drugs Aging. 2006. PMID: 16823993 Review.
-
Management of Patients at High Risk for Pancreatic Cancer.Curr Treat Options Gastroenterol. 2003 Oct;6(5):349-358. doi: 10.1007/s11938-003-0037-2. Curr Treat Options Gastroenterol. 2003. PMID: 12954141
-
Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells.PLoS One. 2013 Dec 5;8(12):e82282. doi: 10.1371/journal.pone.0082282. eCollection 2013. PLoS One. 2013. PMID: 24340014 Free PMC article.
-
Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses.J Clin Pathol. 2005 Dec;58(12):1315-20. doi: 10.1136/jcp.2004.022707. J Clin Pathol. 2005. PMID: 16311354 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical